2. Academic Validation
  3. Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci

Activity of retapamulin (SB-275833), a novel pleuromutilin, against selected resistant gram-positive cocci

  • Antimicrob Agents Chemother. 2006 Jul;50(7):2583-6. doi: 10.1128/AAC.01432-05.
Ronald N Jones 1,  Thomas R Fritsche,  Helio S Sader,  James E Ross
Affiliations

Affiliation

  • 1 JMI Laboratories, Inc., North Liberty, IA 52317, USA.
PMID: 16801451 DOI: 10.1128/AAC.01432-05
Abstract

Retapamulin (SB-275833), the first pleuromutilin to be developed for human topical use, was tested against a selected population of staphylococci and beta-hemolytic streptococci. The MIC90 results for retapamulin were 0.12 microg/ml for Staphylococcus aureus and < or = 0.03 microg/ml for Streptococcus pyogenes; no cross-resistance was observed for organism subsets resistant to oxacillin, erythromycin, or mupirocin.

Figures
Products
嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z